Gelsi-Boyer V, Vey N. Avancées dans la prise en charge des syndromes myélodysplasiques.
Rev Med Interne 2006;
27:600-9. [PMID:
16713027 DOI:
10.1016/j.revmed.2006.02.008]
[Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2005] [Accepted: 02/03/2006] [Indexed: 11/22/2022]
Abstract
OBJECTIVES
Myelodysplastic syndromes (MDS) are a group of clonal hematologic disorder, which combine ineffective hematopoiesis and evolution to acute myeloid leukemia. Significant progress has been made in the understanding of the disease pathogenesis, diagnostics and classification. Promising new agents and innovative therapeutic strategies are currently used. In this article we will review these achievements and their impact on the treatment of MDS.
CURRENT KNOWLEDGE AND KEY POINTS
The pathogenesis of MDS involves abnormalities of the MDS clone itself such as abnormal apoptosis, signalling or epigenetic regulation and abnormalities of the microenvironment such as immune deregulation or increased angiogenesis, which represent potential therapeutic targets. There is currently no standard treatment for MDS and allogeneic stem cell transplantation remains the only curative strategy. However, besides conventional chemotherapy and growth factors, new agents including hypomethylating agents, antiangiogenic drugs, immune modulatory agents have proved effective.
FUTURE PROSPECTS AND PROJECTS
The interesting results achieved with these new agents show that it is necessary to continue investigation in order to improve therapeutic strategies in MDS.
Collapse